A nicotine oral delivery product includes a composition enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and dissolved compounds of the composition, the composition including a source of nicotine and a cellulose or cellulose derivative, wherein the cellulose or cellulose derivative is in granular form. A method of making the nicotine oral delivery product is also provided.

The coronavirus SARS-Cov-2 which started in Wuhan, China, in December 2019 induced a threat to global health. Patients with mental disorders were thought to be at increased risk of becoming infected for several reasons but very much to the inventors' surprise, these psychiatric units remained nearly empty during the lock-down period as if psychiatric patients were protected from SARS-Cov-2 infection. Thus the inventors mined the literature to identify approved drugs with in vitro antiviral activities with a special emphasis on psychotropic drugs and compared these molecules using chemoinformatics strategies to the drugs most commonly used in their psychiatric department. A large number of compounds were found to be cationic amphiphilic drugs (CADs) and as such tend to also be phospholipidosis inducers in vitro (PLD). Several molecules most commonly used in their department were also found to have in vitro antiviral activity and/or can be clustered with compounds with known in vitro antiviral activity. Thus, drugs most commonly used for mental disorders with known in vitro antiviral activities are often CADs. In silico and in vitro analyses of these compounds together with the observations made in the department strongly suggest that commonly used psychotropic drugs and some related anti-histamine agents used as anxiolytics should protect psychiatric patients from SARS-Cov-2 infection.

The coronavirus SARS-Cov-2 which started in Wuhan, China, in December 2019 induced a threat to global health. Patients with mental disorders were thought to be at increased risk of becoming infected for several reasons but very much to the inventors' surprise, these psychiatric units remained nearly empty during the lock-down period as if psychiatric patients were protected from SARS-Cov-2 infection. Thus the inventors mined the literature to identify approved drugs with in vitro antiviral activities with a special emphasis on psychotropic drugs and compared these molecules using chemoinformatics strategies to the drugs most commonly used in their psychiatric department. A large number of compounds were found to be cationic amphiphilic drugs (CADs) and as such tend to also be phospholipidosis inducers in vitro (PLD). Several molecules most commonly used in their department were also found to have in vitro antiviral activity and/or can be clustered with compounds with known in vitro antiviral activity. Thus, drugs most commonly used for mental disorders with known in vitro antiviral activities are often CADs. In silico and in vitro analyses of these compounds together with the observations made in the department strongly suggest that commonly used psychotropic drugs and some related anti-histamine agents used as anxiolytics should protect psychiatric patients from SARS-Cov-2 infection.

Compositions for use in the oral or nasal cavity are disclosed. The compositions include a biologically active agent, a matrix forming agent comprising β-glucan and a filling agent. The compositions can further include additional excipients such as antioxidants, preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. Methods of producing the compositions are also disclosed.

Compositions for use in the oral or nasal cavity are disclosed. The compositions include a biologically active agent, a matrix forming agent comprising β-glucan and a filling agent. The compositions can further include additional excipients such as antioxidants, preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. Methods of producing the compositions are also disclosed.

A battery-operated foam inhalation device which comprises a cartridge (610) having a liquid for producing a foam and a foam outlet (654). Agitation means agitates the liquid to produce the foam, and the agitation means comprises an electric motor (762) and a battery (760) for energising the electric motor (762). A carrier (672) receives the cartridge (610) and has a carrier foam inlet (680) for fluid communication with the foam outlet (654) of the cartridge (610). A carrier foam outlet (682) dispenses the foam to a user.

A moist, layered bioadhesive patch includes one or more polymers. A method of producing a monolayered film and a method of drying said film is provided. Additionally, there is provided a method of producing bioadhesive, layered patches by combining layers of the monolayered film to obtain a desired thickness of the patch. Patches according to the invention may be used as such, or for delivering pharmaceutically active compounds, such as in a drug delivery system.

A moist, layered bioadhesive patch includes one or more polymers. A method of producing a monolayered film and a method of drying said film is provided. Additionally, there is provided a method of producing bioadhesive, layered patches by combining layers of the monolayered film to obtain a desired thickness of the patch. Patches according to the invention may be used as such, or for delivering pharmaceutically active compounds, such as in a drug delivery system.

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.